← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodyUCB PharmaPhase 3

CDP870 (Certolizumab Pegol, Certolizumab Pegol (CDP870))

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Phase3#인기#항체+3
효능 ORR 5%임상시험 57상태 ACTIVE
AntibodystalePfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
AntibodyRochederuxtecan alone or followe…Phase 3

trastuzumab (Herceptin, Paclitaxel + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 80%임상시험 57상태 RECRUITING
AntibodystaleIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
AntibodystaleAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING
AntibodystaleJanssenApproved

Guselkumab (Guselkumab)

Psoriasis; Atopic Dermatitis · Skin Inflammation

#SkinInflammation#Antibody#Approved#인기#항체+5
임상시험 55상태 RECRUITING
AntibodystaleTracon Pharmaceuticals Inc.Phase 2

Androgen receptor inhibitor (Androgen receptor inhibitor)

Prostate Cancer · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+4
임상시험 54상태 RECRUITING
AntibodystalePfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodystaleGSKvedotin) against targets ex…Approved

Mepolizumab (Mepolizumab)

Chronic Rhinosinusitis With Nasal Polyps; Asthma; Eosinophilic · Asthma

#Asthma#Antibody#Approved#인기#항체+5
효능 ORR 90.3%임상시험 54상태 ACTIVE
AntibodyJiangsu Hansoh Pharmaceutical C…vedotin (RC48) in combinati…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#인기#항체+5
임상시험 54상태 RECRUITING
AntibodystaleRocheVedotin on Brain Metastases…Phase 2

atezolizumab (Tecentriq, Atezolizumab - 28 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#인기#항체+5
효능 ORR 90%임상시험 53상태 RECRUITING
AntibodystaleAstraZenecaPreclinical

Benralizumab (Benralizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#인기#항체+4
임상시험 53상태 ACTIVE
AntibodystaleEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#인기#항체+5
임상시험 53상태 RECRUITING
AntibodyRocheDM1 lossPhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#인기#항체+5
효능 ORR 95%임상시험 52상태 RECRUITING
Antibodystale3D Medicines (Sichuan) Co., Ltd.Phase 2

Envafolimab (Envafolimab)

Prostate Cancer; CDK12 Gene Mutation · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
임상시험 52상태 RECRUITING
AntibodystaleJanssenderuxtecan, datopotamab der…Phase 3

Amivantamab (Amivantamab)

Carcinoma, Non-Small-Cell Lung · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+5
효능 ORR 4.3%임상시험 51상태 RECRUITING
AntibodystaleSeagenvedotin-containing regimen …Phase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#인기#항체+5
효능 ORR 89.5%임상시험 51상태 DISCONTINUED
AntibodystaleRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
AntibodystalePfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
AntibodystaleNYU Langone HealthPhase 2

belimumab (belimumab)

Rheumatic Disease · Systemic Lupus Erythematosus (SLE)

#SystemicLupusErythematosusSLE#Antibody#Phase2#인기#항체+5
효능 ORR 48.4%임상시험 51상태 RECRUITING

5 / 62 페이지

← 이전다음 →